Contemporary evidence supporting the appropriate role of a treatment option for HABP/VABP

Posted 8 days ago by Annaleen Nehr

This announcement has 1 attachment:

Merck dinner lecture (260 KB)

Contemporary Evidence Supporting the Appropriate Role of a Treatment Option for HABP/VABP

Date/Start time: 9/16/2025, 5:30 PM

Date/End time: 9/16/2025, 7:00 PM

Herbies

8100 Maryland Avenue

Clayton, MO 63105

Featured Speaker:
Amesh Adalja, MD

Learning Objectives:

Review the epidemiology of common gram-negative bacteria associated with HABP/VABP
Examine clinical data supporting a treatment option for certain patients with HABP/VABP
Discuss the appropriate role of a treatment option for HABP/VABP, including pathogen coverage and recent guidance

Join us for an evening of education, networking, and discussion over dinner as we explore current evidence and best practices in managing HABP/VABP.

Please RSVP by 9/16/2025

Amesh Adalja, M.D is a Senior Scholar and Adjunct Assistant Professor at the Center for Health Security at the Bloomberg School of Public Health at Johns Hopkins University. Dr. Adalja attended American University the Caribbean and completed a residency program in Internal Medicine and Emergency Medicine at Allegheny General Hospital. Dr. Adalja completed postgraduate training in Infectious Diseases and Critical Care Medicine at the University of Pittsburgh. Dr. Adalja is board certified in the areas of Internal Medicine, Emergency Medicine, Infectious Diseases, and Critical Care Medicine. Dr. Adalja is a member of several professional societies, including the Society of Critical Care Medicine and is a fellow of the Infectious Diseases Society Of America.

To register for the event, please contact Merck representative Katie Milsap at katherine.milsap@merck.com